This inventor holds 1 USPTO granted patent. Top assignee: The Salk Institute. Active years: 1986.
Company Filing History:
Years Active: 1986
Title: Paul E. Brazeau: Innovator in Peptide Research
Introduction
Paul E. Brazeau is a notable inventor based in Outremont, Canada. He has made significant contributions to the field of peptide research, particularly in the area of growth hormone stimulation in mammals. His work has implications for both veterinary medicine and aquaculture.
Latest Patents
Paul E. Brazeau holds a patent for a synthetic peptide known as Ovine GRF. This peptide is extremely potent in stimulating the release of pituitary growth hormone (GH) in mammals, especially in sheep. The peptide replicates the native hormone-releasing factor of the sheep hypothalamus and contains a specific amino acid sequence that is crucial for its function. The therapeutic applications of this peptide include accelerating growth in warm-blooded non-human animals and improving aquaculture practices.
Career Highlights
Brazeau is affiliated with the Salk Institute, a prestigious research institution known for its innovative work in biological sciences. His research has focused on the development of biologically active fragments and analogs of the Ovine GRF peptide, which may be administered therapeutically to enhance growth and health in various animal species.
Collaborations
Throughout his career, Paul E. Brazeau has collaborated with esteemed colleagues such as Nicholas C. Ling and Peter Bohlen. These collaborations have furthered the understanding and application of peptide research in practical settings.
Conclusion
Paul E. Brazeau's contributions to peptide research, particularly through his patent on Ovine GRF, highlight his role as an innovator in the field. His work continues to influence veterinary medicine and aquaculture, showcasing the importance of scientific advancements in improving animal health and growth.